Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from AstraZeneca ( (GB:AZN) ) is now available.
The Capital Group Companies, Inc. has adjusted its holdings in AstraZeneca PLC, crossing a threshold of 4.997854% in voting rights as of August 19, 2025. This change in holdings may impact AstraZeneca’s shareholder dynamics and influence its strategic decisions, reflecting ongoing shifts in investor confidence and market positioning.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
More about AstraZeneca
AstraZeneca PLC is a UK-based pharmaceutical company that operates globally. It is primarily focused on the research, development, and commercialization of prescription medicines, with a market focus on oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology.
Average Trading Volume: 2,330,848
Technical Sentiment Signal: Strong Buy
Current Market Cap: £182.6B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.